Mucopolysaccharodisis Treatment Market

Mucopolysaccharodisis Treatment Market Size (2023 to 2028)

The worldwide mucopolysaccharidosis treatment market was valued at USD 2265.7 million in 2023 and is anticipated to reach nearly USD 4079.95 million by 2028, with a rise in CAGR of 10.3% from 2023 to 2028.

MARKET DRIVERS:

The increasing product approval by regulatory authorities for the enhancement of treatment outcomes is one of the key drivers boosting the growth of the market during the projected period. The market's major competitors are concentrating on gaining approval for their modern treatments, which are anticipated to fuel market expansion throughout the forecast period. For instance, a global biotechnology business named Biomarine Pharmaceuticals Inc. declared in June 2021 that it would be creating and marketing novel biopharmaceuticals for rare conditions with hereditary aetiology. The National Medical Products Administration (NMPA) had granted permission for Vimizim (elosulfase alfa) for use in the treatment of patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. The first medication for this illness to be approved in China is rimizim.

The adoption of inorganic growth strategies by prominent key players is another driver propelling market growth over the projected period. Major firms are anticipated to adopt inorganic growth methods, such as partnerships and collaborations, to increase their market share. For instance, in May 2021, a contract manufacturing organization (CMO) and aseptic fill and finish services expert company, Rentschler Fill Solutions, and Ultragenyx Pharmaceutical Inc., a company focused on developing the first-ever approved treatments for rare and ultra-rare diseases and moving the rare disease community forward, partnered for the production of injectable Mepsevii (vestronidase alfa), a synthetic form of the human enzyme beta-glucuronidase, to treat rare hereditary disorder.

The emerging demand for various medications to treat the symptoms of conditions such as lysosomal storage disease is further fuelling the market growth during the forecast period. The growing market for MPS treatments is being driven by the increasing demand for various pharmaceuticals for dealing with the signs and symptoms of lysosomal storage diseases, such as mucopolysaccharidosis. The market for treating MPS and other LSDs is growing as researchers and pharmaceutical companies create novel drugs and therapies to deal with the underlying enzyme deficiencies driving these diseases and boosting the market growth. 

The other factors that contributed to the overall market expansion include growing government initiatives by both public and private organizations, growing government funding, and increasing research and development activities for the MPS treatment. 

MARKET RESTRAINTS:

The lack of favorable reimbursement policies and poor health awareness are the two major obstacles hampering the market growth during the projected period. The amount of financial support patients receive for their medical treatments is heavily influenced by reimbursement policies. Due to the specialized nature of their care, treatments for uncommon and complicated diseases like MPS can be expensive. Patients may find it difficult to afford the required therapies if there are insufficient or unfavorable reimbursement regulations in place, which could impede market expansion. Lack of information among the population as a whole and the medical community is a major problem for rare diseases like MPS. This may result in delayed or incorrect diagnoses, delaying the initiation of treatment for patients. Low awareness may also have an impact on the funding of research and pharmaceutical development initiatives. Hence, these two factors majorly hamper the market growth during the forecast period. 

Impact of COVID-19 on the mucopolysaccharodisis treatment market:

The pandemic crisis has created challenges for the Mucopolysaccharodisis treatment market. The large focus on treating the patients affected by the pandemic led to delays in research and clinical trials for the MPS treatment, which potentially affected their development and approval timelines. The pandemic also affected the accessibility of MPS treatment for patients who required regular in-person care or hospital visits. The pandemic created a financial burden in every sector; every individual and government faced economic challenges that could have affected healthcare spending and insurance coverage for the MPS treatment. However, the market share started to grow at a higher rate in 2022. 

REPORT COVERAGE:

This research report on the global mucopolysaccharidosis treatment market has been segmented and sub-segmented based on the product type, application and region.

Mucopolysaccharidosis Treatment Market- By Treatment Type:

• Enzyme Replacement Therapy
• Stem Cell Therapy 

Based on the treatment type, the enzyme replacement therapy segment is anticipated to hold the dominant position in the market during the projected period. For people with MPS, ERT showed encouraging outcomes in terms of treating symptoms and enhancing quality of life. It treats the disease's fundamental cause, making it a highly effective therapy option. The need for potent medications like ERT rises as knowledge about MPS and its treatments expands. Healthcare professionals and patients are actively looking for treatments that can address the disease's underlying causes. Enzyme replacement therapy for MPS has been developed and improved, resulting in improvements in biotechnology and pharmaceutical research. The market's potential for segment expansion is positively impacted by this innovation.

The stem cell therapy segment is also expected to hold a notable share of the market during the projected period. For the treatment of MPS, stem cell therapy offers a regenerative strategy. It seeks to exchange out cells that are dysfunctional for functioning ones, which could result in long-lasting improvements in symptoms and general health.

Mucopolysaccharidosis Treatment Market – By MPS Type:

• MPS-I
• MPS-II
• MPS-IV
• MPS-VI
• MPS-VII
• Others (MPS-III and MPS-IX) 

Based on the MPS type, the MPS-II segment is expected to grow at a significant CAGR during the forecast period owing to the rising prevalence of the MPS-II in addition to the availability of treatment options. 

The MPS-IV segment is also predicted to hold a considerable share of the market during the forecast period. 

Mucopolysaccharidosis Treatment Market – By End-user:

• Hospitals
• Specialty Clinics
• Others

Based on the end-user, the hospital segment is expected to dominate the market during the forecast period due to rising healthcare expenditure, which led to the enhancement of the treatment options for patients suffering from MPS. 

The specialty clinic segment is also anticipated to hold a substantial share of the market during the forecast period. 

Mucopolysaccharidosis Treatment Market – By Region:

• North America
• Latin America
• Europe
• Asia-Pacific
• Middle East and Africa

Based on the region, the North American region is expected to hold the dominant position in the market and is projected to grow at 35.2% of the market share during the projected period. The market for treating mucopolysaccharidosis (MPS) is anticipated to expand significantly as a result of manufacturers' increased focus on creating innovative treatments. Throughout the forecast period, an increase in product launches and approvals in the North American region is anticipated to boost market expansion. For instance, in August 2022, REGENXBIO Inc., a clinical-stage biotechnology firm looking to improve lives through the curative potential of gene therapy, announced its intentions to use the U.S. FDA's accelerated approval pathway for RGX-121 to treat mucopolysaccharidosis Type II (MPS II) by submitting a Biologics Licence Application (BLA) in 2024. During a phase I dose-escalation clinical study in adults with mucopolysaccharidosis, Homology Medicines, Inc., a company that develops genetic medicines, presented data on HMI-203, a gene therapy candidate for the treatment of Hunter syndrome (MPS II), at the annual WorldSymposium Meeting held in the United States in February 2022.

Europe region is also expected to show lucrative growth in the market during the forecast period. Strong healthcare infrastructure, excellent research, regulatory support, involvement of patients, and government initiatives in the European region all work together to fuel the expansion of the market for mucopolysaccharidosis treatments. These elements support the availability of cutting-edge and efficient treatment options for MPS patients throughout Europe.

APAC region is expected to grow at a healthy CAGR during the forecast period. The market for mucopolysaccharidosis treatments is expanding with rising healthcare spending, rising awareness, and cooperative efforts within the APAC region. More people in this region may have access to efficient MPS treatments as the region's healthcare system and research capacity improve.

Latin America, the Middle East, and Africa are also expected to hold a significant share of the market during the projected period. 

KEY MARKET PLAYERS:

The prominent key player in the global Mucopolysaccharidosis treatment market is Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.

RECENT MARKET DEVELOPMENTS:

• In September 2022, The UK MHRA, Research Ethics Committee (REC), and Health Research Authority (HRA) have given their approval to AVROBIO's (Lentiviral-Based Gene Therapy) collaborators for the start of the Phase 1/2 clinical trial of investigational autologous hematopoietic stem cell (HSC) gene therapy in infants with neuronopathic mucopolysaccharidosis or hunter disease.
• In February 2022, The World Symposium featured new, more stable data from an ongoing phase 1/2 clinical trial of DNL310, an investigational brain-penetrant enzyme replacement therapy aimed to treat both the central nervous system and peripheral manifestations of MPS II (Hunter syndrome), presented by Denali Therapeutics Inc., a company committed to eradicating neurodegenerative diseases through rigorous therapeutic discovery and development.
• In June 2022, More than 80 proposals were presented at the International Liver Congress (ILC) 2022, which will take place from June 22–26, 2022, according to Gilead Sciences, Inc. A research-based biopharmaceutical firm focused on the discovery, development, and commercialization of new medicines. The Week 48 primary endpoint data from the pivotal Phase 3 program of Hepcludex (bulevirtide), testing its effectiveness and safety for the treatment of hepatitis delta virus (HDV), as well as the influence of the medication on patient-reported outcome, were among the major oral presentations.